{"id":51432,"date":"2025-12-18T22:24:53","date_gmt":"2025-12-18T14:24:53","guid":{"rendered":"https:\/\/flcube.com\/?p=51432"},"modified":"2025-12-18T22:24:54","modified_gmt":"2025-12-18T14:24:54","slug":"insilico-medicine-debuts-on-hkex-in-2-3b-ipo-valuing-ai-drug-platform-at-1-5b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51432","title":{"rendered":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B"},"content":{"rendered":"\n<p><strong>InSilico Medicine Cayman TopCo<\/strong> (HKG: 3696) officially listed on the <strong>Hong Kong Stock Exchange<\/strong>, offering <strong>94,690,500 shares<\/strong> at <strong>HK$24.05 per share<\/strong>, raising <strong>HK$2.277 billion<\/strong> (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its <strong>Pharma.AI platform<\/strong> to generate assets now in clinical and IND\u2011enabling stages, with <strong>three out\u2011licensed programs<\/strong> worth up to <strong>USD\u202f2.1\u202fbillion<\/strong> in potential milestones.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-details\">IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Ticker<\/strong><\/td><td>3696.HK<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>94,690,500 shares (global offering)<\/td><\/tr><tr><td><strong>Price per Share<\/strong><\/td><td>HK$24.05<\/td><\/tr><tr><td><strong>Total Raise<\/strong><\/td><td>HK$2.277 billion (\u2248\u202fUS$292\u202fmillion)<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Advance internal Pipeline, expand Pharma.AI platform, fund clinical trials<\/td><\/tr><tr><td><strong>Post\u2011IPO Valuation<\/strong><\/td><td>Implied market cap: \u2248\u202fUS$1.5\u202fbillion (based on offer price)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-overview\">Company Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Founded<\/th><th>Business Model<\/th><th>Core Technology<\/th><\/tr><\/thead><tbody><tr><td><strong>2014<\/strong><\/td><td>AI\u2011driven drug discovery and development<\/td><td>Pharma.AI generative AI platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-milestones\">Key Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Achievement<\/th><\/tr><\/thead><tbody><tr><td><strong>Asset Pipeline<\/strong><\/td><td><strong>20+ assets<\/strong> in clinical or IND\u2011enabling stages<\/td><\/tr><tr><td><strong>Out\u2011Licensing Success<\/strong><\/td><td><strong>3 assets<\/strong> licensed to international pharma; total contract value up to <strong>USD\u202f2.1\u202fbillion<\/strong> (USD\u202f110\u202fM upfront + USD\u202f1.9\u202fB milestones)<\/td><\/tr><tr><td><strong>Internal Development<\/strong><\/td><td><strong>1 Phase\u202fII asset<\/strong> advancing under internal development<\/td><\/tr><tr><td><strong>Platform Validation<\/strong><\/td><td>Pharma.AI platform enables rapid asset generation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For InSilico:<\/strong> <strong>$292\u202fmillion IPO<\/strong> provides runway to advance <strong>Phase\u202fII asset<\/strong> and expand platform; <strong>out\u2011licensing track record<\/strong> validates commercial viability; <strong>HKEX listing<\/strong> enhances global visibility and access to Asian capital markets.<\/li>\n\n\n\n<li><strong>For AI Drug Discovery:<\/strong> Demonstrates <strong>AI\u2011generated assets<\/strong> can achieve <strong>clinical\u2011stage validation<\/strong> and <strong>big pharma partnerships<\/strong>; <strong>20+ asset pipeline<\/strong> showcases platform scalability; positions InSilico as <strong>leader in generative AI for drug development<\/strong>.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> <strong>AI\u2011driven biotech IPO<\/strong> tests investor appetite for <strong>platform\u2011based models<\/strong>; <strong>$2.1\u202fbillion potential licensing value<\/strong> sets benchmark for AI\u2011discovered therapeutics; <strong>H-Share listing<\/strong> (Hong Kong shares) opens door for mainland Chinese investor participation via Stock Connect.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding InSilico\u2019s pipeline advancement, platform expansion, and market penetration. Actual results may differ due to clinical risks, competitive responses, or market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121800032_c_compressed.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121800032_c_compressed.\"><\/object><a id=\"wp-block-file--media-1178544d-2932-4282-9ab1-bf8c24449bcf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121800032_c_compressed.pdf\">2025121800032_c_compressed<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121800032_c_compressed.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1178544d-2932-4282-9ab1-bf8c24449bcf\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51435,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4514,164,72],"class_list":["post-51432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-3696","tag-insilico-medicine","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51432\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B\" \/>\n<meta property=\"og:description\" content=\"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51432\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:24:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-18T14:24:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B\",\"datePublished\":\"2025-12-18T14:24:53+00:00\",\"dateModified\":\"2025-12-18T14:24:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1805-1.webp\",\"keywords\":[\"HKG: 3696\",\"Insilico Medicine\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51432#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51432\",\"name\":\"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1805-1.webp\",\"datePublished\":\"2025-12-18T14:24:53+00:00\",\"dateModified\":\"2025-12-18T14:24:54+00:00\",\"description\":\"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51432\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1805-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1805-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51432#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B - Insight, China&#039;s Pharmaceutical Industry","description":"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51432","og_locale":"en_US","og_type":"article","og_title":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B","og_description":"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.","og_url":"https:\/\/flcube.com\/?p=51432","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-18T14:24:53+00:00","article_modified_time":"2025-12-18T14:24:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51432#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51432"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B","datePublished":"2025-12-18T14:24:53+00:00","dateModified":"2025-12-18T14:24:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51432"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51432#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","keywords":["HKG: 3696","Insilico Medicine","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51432#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51432","url":"https:\/\/flcube.com\/?p=51432","name":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51432#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51432#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","datePublished":"2025-12-18T14:24:53+00:00","dateModified":"2025-12-18T14:24:54+00:00","description":"InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering 94,690,500 shares at HK$24.05 per share, raising HK$2.277 billion (\u2248\u202fUS$292\u202fmillion). The AI\u2011driven drug discovery company, founded in 2014, leverages its Pharma.AI platform to generate assets now in clinical and IND\u2011enabling stages, with three out\u2011licensed programs worth up to USD\u202f2.1\u202fbillion in potential milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51432#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51432"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51432#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","width":1080,"height":608,"caption":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51432#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1805-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51432"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51432\/revisions"}],"predecessor-version":[{"id":51437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51432\/revisions\/51437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51435"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}